Oppenheimer analyst Steven Lichtman raised his price target for Stryker (SYK) to $135 from $122 on valuation. After surveying orthopedic surgeons, the analyst says hip/knee market appears stable thus far in 2017. On robotics, Lichtman points out that the majority does not expect to use Stryker's Mako with Triathlon at this point, citing lack of data and cost were cited. It is early in the rollout and Stryker education efforts will ramp now post-AAOS, he notes, adding that he continues to see uptake as being steadier rather than rapid. The analyst has a Perform rating on the shares, and says he prefers Zimmer Biomet (ZBH) near-term on valuation.